Heinzelmann, Frank and Bethge, Wolfgang and Beelen, Dietrich Wilhelm and Stelljes, Matthias and Dreger, Peter and Engelhard, Marianne and Finke, Juergen and Kroeger, Nikolaus and Holler, Ernst and Bornhaeuser, Martin and Mueller, Annerose and Haubitz, Imme and Ottinger, Hellmut (2018) Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 144 (6). pp. 1173-1183. ISSN 0171-5216, 1432-1335
Full text not available from this repository. (Request a copy)Abstract
Purpose In patients with follicular lymphoma, secondary transformation to aggressive lymphoma (tFL) implies a poor prognosis. In principle, allogeneic haematopoietic cell transplantation (allo-HCT) offers a chance of cure for tFL but is rarely practiced. Aim of this retrospective multicenter study was to define the actual significance of allo-HCT in treatment of tFL. Methods The database of the German Registry for Stem Cell Transplantation (DRST) was screened for patients who underwent allo-HCT for tFL 1998-2008. Confirmation of tFL-diagnosis by local and/or pathologists of the National NHL Board was mandatory for enrolment. Gaps in reported EBMT Minimum Essential Data datasets (MED-A) were filled by local DRST data managers. Relevant HCT outcome variables were evaluated by uni- and multivariate statistical analysis. Results Median age of enrolled 33 patients was 51 years with a post allo-HCT median follow-up of 7.1 years of surviving patients. At time of HCT 24/33 patients had chemosensitive disease. In 24/33 patients reduced intensity conditioning (RIC) was used. Estimated 1, 2, 5-year overall survival (OS) and event-free survival rates were 49/39/33, and 33/30/24%. Cumulative 100 days non-relapse mortality was 25%. Chemosensitive disease, RIC, and limited chronic GvHD were identified as independent prognostic factors for OS. Conclusions Allo-HCT offers the chance of cure for tFL.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NON-HODGKINS-LYMPHOMA; BONE-MARROW; INDOLENT; RITUXIMAB; OUTCOMES; GRAFT; BLOOD; DONOR; Allogeneic HCT; Transformed follicular lymphoma; Prognostic factors; Cure |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 Feb 2020 12:54 |
| Last Modified: | 19 Feb 2020 12:54 |
| URI: | https://pred.uni-regensburg.de/id/eprint/14542 |
Actions (login required)
 |
View Item |
